Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




GEN News Highlights: Back to Item

Baxter Nabs Archemix' Lead Synthetic Hemophilia Candidate and Assets for About $30M

ARC19499 is undergoing Phase I evaluation to block TFPI activity and increase blood clotting.



Click here to log in or to register for free.

You will be taken back to your selected item after log-in/registration.

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll